• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful?

作者信息

Borozan Sanja, Vujosevic Snezana, Mikhailidis Dimitri P, Muzurovic Emir

机构信息

Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro.

Faculty of Medicine, University of Montenegro, Podgorica, Montenegro.

出版信息

Curr Vasc Pharmacol. 2025;23(1):4-7. doi: 10.2174/0115701611340703240809044916.

DOI:10.2174/0115701611340703240809044916
PMID:39129278
Abstract
摘要

相似文献

1
Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful?代谢功能障碍相关脂肪性肝炎与心血管疾病预防——瑞美替昂有用吗？
Curr Vasc Pharmacol. 2025;23(1):4-7. doi: 10.2174/0115701611340703240809044916.
2
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.Resmetirom用于治疗代谢功能障碍相关脂肪性肝炎（MASH）：当前证据与治疗潜力的全面综述
Cureus. 2024 Nov 29;16(11):e74772. doi: 10.7759/cureus.74772. eCollection 2024 Nov.
3
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).瑞美替隆：首个获美国食品药品监督管理局批准用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
4
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.选择性甲状腺激素受体-β激动剂 Resmetirom 治疗代谢功能障碍相关脂肪性肝病（MASLD）的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2024 Aug 26;14(1):19790. doi: 10.1038/s41598-024-70242-8.
5
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals.雷西莫特罗姆与代谢相关脂肪性肝炎：全球医疗保健专业人士对多学科管理的观点。
Curr Obes Rep. 2024 Dec;13(4):818-830. doi: 10.1007/s13679-024-00582-z. Epub 2024 Aug 7.
6
Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease.用于代谢功能障碍相关脂肪性肝炎的雷斯美洛：针对肝脏和心血管疾病
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1034-1037. doi: 10.21037/hbsn-24-568. Epub 2024 Nov 14.
7
Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis.瑞美替隆治疗代谢功能障碍相关脂肪性肝炎（MASH）的安全性和有效性：一项系统评价和荟萃分析
Eur J Gastroenterol Hepatol. 2025 Apr 1;37(4):395-402. doi: 10.1097/MEG.0000000000002901. Epub 2024 Dec 3.
8
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.在一项为期52周、双盲、随机、安慰剂对照的III期研究中，对患有代谢功能障碍相关脂肪性肝炎（MASH）和纤维化的患者进行与健康相关的生活质量（HRQL）评估，该研究使用resmetirom（MGL-3196）。
Hepatology. 2025 Apr 1;81(4):1318-1327. doi: 10.1097/HEP.0000000000001084. Epub 2024 Sep 6.
9
Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis.肝脏甲状腺激素受体-β信号传导：代谢功能障碍相关脂肪性肝炎治疗的机制与最新进展
Diabetes Obes Metab. 2025 Apr;27(4):1635-1647. doi: 10.1111/dom.16117. Epub 2024 Dec 10.
10
Effectiveness of Resmetirom in Reducing Cholesterol Levels in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.Resmetirom降低非酒精性脂肪性肝炎患者胆固醇水平的有效性：一项系统评价和荟萃分析。
Cureus. 2024 Oct 4;16(10):e70859. doi: 10.7759/cureus.70859. eCollection 2024 Oct.

引用本文的文献

1
Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies.不同表达系统构建Fc-FGF21及其与艾弗司明在体内外研究中的异同比较
Appl Biochem Biotechnol. 2025 Apr;197(4):2180-2196. doi: 10.1007/s12010-024-05107-x. Epub 2024 Dec 19.

本文引用的文献

1
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.脂肪性肝病：病理生理学与新兴药物治疗
Pharmacol Rev. 2024 May 2;76(3):454-499. doi: 10.1124/pharmrev.123.001087.
2
Liver Fibrosis and Atherosclerosis, a Consequence of Metabolic Dysfunction-Do They Share a Similar Pathophysiological Background?肝纤维化与动脉粥样硬化——代谢功能障碍的后果，它们是否具有相似的病理生理背景？
Angiology. 2025 Sep;76(8):717-719. doi: 10.1177/00033197241234076. Epub 2024 Feb 15.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.雷美替胺治疗非酒精性脂肪性肝病：一项随机、双盲、安慰剂对照的 3 期临床试验。
Nat Med. 2023 Nov;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1. Epub 2023 Oct 16.
5
Resmetirom for nonalcoholic steatohepatitis.用于非酒精性脂肪性肝炎的瑞美替隆
J Manag Care Spec Pharm. 2023 Oct;29(10):1169-1172. doi: 10.18553/jmcp.2023.29.10.1169.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识：新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
7
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
8
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
9
Non-alcoholic Fatty Liver Disease in Children.儿童非酒精性脂肪性肝病
Curr Vasc Pharmacol. 2023;21(1):4-25. doi: 10.2174/1570161121666221118155136.
10
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.瑞美替隆的早期成本效益和价格阈值分析：一种用于治疗非酒精性脂肪性肝炎的研究性疗法
Pharmacoecon Open. 2023 Jan;7(1):93-110. doi: 10.1007/s41669-022-00370-2. Epub 2022 Sep 14.